Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs iShares MSCI China ETF (MCHI) Price & Performance

Ascendis Pharma A/STrade
iShares MSCI China ETFTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs iShares MSCI China ETF — how do they compare? Ascendis Pharma A/S trades at $256.5 (market cap $16.67B), while iShares MSCI China ETF trades at $54.82. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.

ASNDMCHI
Market Cap
$16.67B
Sector
HealthBroad Market / Factor
52-Week High
$277.18$66.99
52-Week Low
$189.74$50.48
Enterprise Value
$17.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.

ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.

iShares MSCI China ETF

MCHI trades at $55.08, down 3.25% today amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. The ETF's valuation appears historically cheap compared to US indices, with recent news highlighting China's strong export performance and institutional buying activity. A dividend of $0.36 is scheduled for June 2026.

MCHI presents a value opportunity with significant discount to historical averages, supported by China's export strength and AI infrastructure investments. Risks include US-China trade tensions and potential regulatory changes. Institutional interest is mixed with recent buying by Empowered Funds offset by selling from Acima Private Wealth.

Returns comparison

Trailing returns across standard periods

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About iShares MSCI China ETF

MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.

Read more on MCHI